Wansu Park

Levels of aripiprazole in the blood with an injection of aripiprazole administered once every two months: a plain language summary of publication

Yanlin Wang, Matthew Harlin, Frank Larsen, X. Wang et autres

What is this summary about? The information summarized here relates to aripiprazole, a medicine that is used to treat conditions such as schizophrenia and bipolar I disorder. Researchers wanted to understand what levels of aripiprazole in the blood looked like following an …

us, dk (code pays fourni par la source)

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension

Akshay S. Desai, Adam D. Karns, Jolita Badarienė, Ahmad Aswad et autres

Importance: In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months. Objective: To evaluate the efficacy and safety of zilebesiran …

us, lt, gb (code pays fourni par la source)

A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole

Andrea M. Fagiolini, Yanlin Wang, Miquel Bioque, Matthew Harlin et autres

gluteal intramuscular injection once every two months. This review examines population pharmacokinetic model-based simulations relevant to the use of Ari 2MRTU in Europe, accompanied by expert commentary that contextualizes the simulations and highlights the potential implications of the availability of Ari 2MRTU …

it, es, us, dk (code pays fourni par la source)

ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY

Manish Saxena, Ahmad Aswad, Jolita Badarienė, Farhana Kazi et autres

Objective: Zilebesiran is an investigational RNA interference therapeutic that targets hepatic angiotensinogen, the most upstream precursor of the renin-angiotensin system. In the Phase 2 KARDIA-1 study, single subcutaneous (SC) doses of zilebesiran monotherapy significantly reduced 24-hr mean ambulatory and office systolic blood …

gb, lt, us (code pays fourni par la source)

Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2‐Month Ready‐to‐Use Long‐Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder

Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang et autres

A ready-to-use (RTU) long-acting injectable (LAI) formulation of aripiprazole monohydrate for administration once every 2 months, available in 960 mg (Ari 2MRTU 960) or 720 mg doses, has been developed for the treatment of schizophrenia or bipolar I disorder. A previously developed …

us, dk (code pays fourni par la source)

Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy

Wansu Park, Megan Melch, Jong-Tae Lee, Prajakta S. Badri et autres

A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD

Kristen L. Nowak, Rahul K. Kakkar, Matt Devalaraja, Larry Lo et autres

Background Chronic systemic inflammation is highly prevalent in patients with CKD (measured as an elevated high-sensitivity C-reactive protein, hsCRP) and independently associated with cardiovascular events and all-cause mortality. An IL-6 blocker to suppress inflammation represents a potential novel paradigm to reduce cardiovascular …

us (code pays fourni par la source)